RPG Life Sciences reported Q4 FY26 revenue growth of 23.6% YoY to ₹176.9 crores with EBITDA margin of 25.6%.
Domestic Formulations grew 18.2%, outperforming Indian Pharma Market growth of 10.1% in Q4.
API division registered 144.3% growth in Q4 following restoration of manufacturing unit after January 2025 fire.
Board recommended final dividend of ₹24 per share (300%) for FY25-26, subject to shareholder approval.